EyePoint Pharmaceuticals' stock dropped sharply after its wet AMD drug DURAVYU missed the primary trial endpoint, though an adjusted analysis showed it matched the standard treatment and cut treatment burden by 42%. Despite the setback, a Jefferies analyst set a price target of $8.00, implying a 73.72% upside from the current price of around $4.61. The stock's decline reflects investor caution, but the analyst's positive outlook highlights potential value in the drug's secondary benefits and future market prospects. EyePoint's market cap is now about $382 million, with high trading volume signaling active investor interest.
Gossamer Bio stands out in the biotech sector by generating a Return on Invested Capital (ROIC) of 697.21%, vastly exceeding its Weighted Average Cost of Capital (WACC) of 6.57%. This results in an ROIC to WACC ratio of 106.17, meaning the company cr...
Mercury Systems, a defense technology firm, is expected to exceed its upcoming earnings estimates, driven by increased global defense spending due to geopolitical tensions. The company supports numerous defense programs and contractors, benefiting fr...
ACCO Brands Corporation, known for products like Five Star and Swingline, is showing promising growth despite a recent 3% dip in its stock price over 10 days. The stock has gained about 5.2% over the past month, suggesting positive momentum. Analysts...
Amer Sports reported a strong Q1 2026 with revenue up 32% and adjusted EBITDA rising over 30% to $432 million, prompting an upward revision of its full-year financial guidance. Key brands like Arc'teryx and Salomon drove this growth across all market...
Argenx's stock surged 16.66% following positive Phase III ALKIVIA trial results for its autoimmune drug Vyvgart Hytrulo, showing significant efficacy in treating autoimmune myositis. Analyst firm William Blair reaffirmed an 'Outperform' rating, refle...
